Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Envudeucitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alumis' Envudeucitinib Succeeds in Phase 3 Psoriasis Trial
    Alumis' Envudeucitinib Succeeds in Phase 3 Psoriasis Trial

    28 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/28/3264196/0/en/Alumis-Envudeucitinib-Delivers-Early-and-Robust-Improvements-in-Skin-Clearance-Quality-of-Life-and-Psoriasis-Symptoms-in-Two-Phase-3-Trials-Underscoring-Its-Potential-as-a-Leading-.html

    GLOBENEWSWIRE
    28 Mar 2026
    Share Share
    Alumis Reveals 2025 Financials And Recent Milestones
    Alumis Reveals 2025 Financials And Recent Milestones

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3259420/0/en/Alumis-Reports-Year-End-2025-Financial-Results-and-Highlights-Recent-Achievements.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    Alumis Unveils Phase 3 Envudeucitinib Psoriasis Data at 2026
    Alumis Unveils Phase 3 Envudeucitinib Psoriasis Data at 2026

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3258105/0/en/Alumis-Announces-Late-Breaker-Oral-Presentation-of-Phase-3-Data-for-Envudeucitinib-in-Moderate-to-Severe-Plaque-Psoriasis-at-2026-American-Academy-of-Dermatology-Annual-Meeting.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    Alumis Announces Phase 3 Breakthrough In Oral Psoriasis Therapy
    Alumis Announces Phase 3 Breakthrough In Oral Psoriasis Therapy

    08 Jan 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/clinical-trials/alumis-reports-breakthrough-phase-3-results-for-oral-psoriasis-therapy-18803

    INDPHARMAPOST
    08 Jan 2026
    Share Share
    Alumis' Envudeucitinib Hits Phase 3 Skin Clearance Goal
    Alumis' Envudeucitinib Hits Phase 3 Skin Clearance Goal

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213465/0/en/Alumis-Envudeucitinib-Delivers-Leading-Skin-Clearance-Among-Next-Generation-Oral-Plaque-Psoriasis-Therapies-in-Phase-3-Program.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.